In vivo syngeneic tumor models with acquired resistance to anti-PD-1/PD-L1 therapies.

Publié le 09/06/2022

In vivo syngeneic tumor models with acquired resistance to anti-PD-1/PD-L1 therapies.

Denis M, Grasselly C, Choffour PA, Wierinckx A, Mathe D, Chettab K, Tourette A, Talhi N, Bourguignon A, Birzele F, Kress E, Jordheim LP, Klein C, Matera EL, Dumontet C.

https://doi.org/10.1158/2326-6066.CIR-21-0802

Cancer Immunology Research, 2022, June

Soutenir la recherche

In vivo syngeneic tumor models with acquired resistance to anti-PD-1/PD-L1 therapies.

In vivo syngeneic tumor models with acquired resistance to anti-PD-1/PD-L1 therapies.